Articles: coronavirus.
-
Southern medical journal · Jan 2022
An Epidemic Supplanted by a Pandemic: Vaping-Related Illness and COVID-19.
Before the coronavirus disease 2019 (COVID-19) pandemic, vaping-related illness was the prevailing public health concern. The incidence of vaping-related illnesses-mainly e-cigarette, or vaping, product use-associated lung injury (EVALI)-went from a peak in September 2019 to a low in February 2020, and the Centers for Disease Control and Prevention decided to discontinue the collection of EVALI case reports. Despite the decrease in EVALI with the arrival of COVID-19, EVALI should still be considered a differential diagnosis for people with COVID-19 for reasons outlined in this review. This narrative review describes vaping devices, summarizes the adverse health effects of vaping on the lungs and other systems, considers the potential interplay between vaping and COVID-19, and highlights gaps in knowledge about vaping that warrant further research.
-
In response to the coronavirus disease-2019 (COVID-19) pandemic, routine clinical visits to the ophthalmic emergency department (OED) were deferred, while emergency cases continued to be seen. ⋯ During the COVID-19 pandemic, the number of OED visits at a tertiary hospital dropped by more than half. Although the drop in visits was mostly due to decrease in non-traumatic-non-urgent cases, there was also decrease in non-traumatic-urgent presentations with possible important visual consequences. Additional studies should elucidate what happened to these patients.
-
Letter Case Reports
Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
The Oxford-AstraZeneca vaccine ChAdOx1 (AZD1222, Vaxzevria) is playing a crucial role in counteracting the coronavirus disease-2019 (COVID-19) pandemic [1]. Since March 2021, reports of unexpected thrombotic events associated with thrombocytopenia and vaccination have been published [2]. To the best of our knowledge there is only one report about vaccination-associated myasthenia gravis (MG) occurring after a second dose of BNT162b2 (Pfizer-BioNTech).
-
Rev Assoc Med Bras (1992) · Jan 2022
Evaluation and follow-up of antibody formation after CoronaVac vaccine.
The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine. ⋯ It is important to make booster doses, as the CoronaVac vaccine will lose its effect after the fifth month due to the decrease in Ab levels. In addition, since the antibody levels decrease later in those who have a history of coronavirus disease 2019 infection and are vaccinated, individuals who have no previous history of coronavirus disease 2019 should be given priority for vaccination.
-
Rev Assoc Med Bras (1992) · Jan 2022
Observational StudyAssociations between muscle strength, dyspnea and quality of life in post-COVID-19 patients.
Patients with severe coronavirus disease 2019 (COVID-19) develop high muscle weakness. The objective of this study was to analyze the physical fitness of post-COVID-19 patients and its relationship with dyspnea and health-related quality of life (HrQoL). ⋯ Higher handgrip strength was associated with lower COVID-19 severity and less sequelae. Therefore, either the patients with severe COVID-19 suffered greater muscle breakdown, or higher muscle strength acted as a mitigating factor for the disease. It is suggested that post-COVID-19 rehabilitation programs should focus on increasing muscle strength. Also, adequate physical fitness could mitigate the physical and mental post-COVID-19 sequelae.